Sandbox endocarditis2: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:


{| class="wikitable" style="margin: 1em auto 1em auto"
__NOTOC__
|+
{{Meningitis}}
! Epidemiological features || Common Microorganism(s)
 
{{CMG}}; '''Associate Editor(s)-In-Chief:'''  {{CZ}}
 
==Medical Therapy==
 
===Pharmacotherapy===
====Empiric Treatment====
* Do not wait for the results of the [[CT scan]] and the [[lumbar puncture]]; empiric treatment should be started as soon as possible.
* Blood cultures should be drawn before starting the [[antibiotic]] therapy, and then the antibiotic treatment should be changed once the blood culture results are out.
 
* Empiric antibiotic treatment should be started within 30 minutes after the patient presentation.
* In case of high suspicion of pneumococcal meningitis in adult patients, 0.15 mg/kg IV Q6H dexomethasone should be administered for 2 to 4 days.
** The first dose of dexomethasone is given along with or 20 minutes prior to starting the antibiotics treatment.
 
{|
|-
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:19em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age <1 Week}}''
|-
|-
| <center>'''Injection drug use'''</center>||
 
*[[S aureus]], including community-acquired
 
*oxacillin-resistant strains
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
*Coagulase-negative [[staphylococci]]
*[[Streptococcus|β-Hemolytic streptococci]]
*[[Fungi]]
*Aerobic Gram-negative bacilli, including
:*Pseudomonas aeruginosa
|-
|-
| <center>'''Indwelling cardiovascular medical devices'''</center> ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 50 mg/kg IV q8h'''''
*[[Staphylococcus aureus|S aureus]]
|-
*Coagulase-negative staphylococci
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
*[[Fungi]]
|-
*Aerobic Gram-negative bacilli
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 100—150 mg/kg/day IV q8—12h'''''
*[[Corynebacterium]] sp
|-
|-
| <center>'''Genitourinary disorders'''</center>


<center>'''Genitourinary infection'''</center>


<center>'''Genitourinary manipulation'''</center>
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 50 mg/kg IV q8h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q12h'''''
|-
|}


<center>'''pregnancy'''</center>


<center>'''Delivery'''</center>
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:19em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age <1 Week}}''
|-
 
 
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 50 mg/kg IV q8h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 100—150 mg/kg/day IV q8—12h'''''
|-
 


<center>'''Abortion'''</center>
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
||
|-
*Enterococcus sp
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 50 mg/kg IV q8h'''''
*Group B [[streptococci]] (S agalactiae)
|-
*[[Listeria]] monocytogenes
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
*Aerobic Gram-negative bacilli
*Neisseria [[gonorrhoeae]]
|-
|-
| <center>'''Chronic skin disorders''' </center>||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q12h'''''
*S aureus
|-
-Hemolytic streptococci
|}
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:19em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age 1—4 Weeks}}''
|-
 
 
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| <center>'''Poor dental health, dental procedures''' </center>||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
*Viridans group streptococci
*“Nutritionally variant streptococci”
*Abiotrophia defectiva
*Granulicatella sp
*Gemella sp
*HACEK organisms
|-
|-
| <center>'''Alcoholism, cirrhosis''' </center>||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
*Bartonella sp
*Aeromonas sp
*[[Listeria]] sp
*[[Streptococcus pneumoniae|S pneumoniae]]
*β-Hemolytic streptococci
|-
|-
| <center>'''Burn patients''' </center>||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 150—200 mg/kg/day IV q6—8h'''''
*[[Staphylococcus aureus|S aureus]]
*Aerobic Gram-negative bacilli, including
:*[[Pseudomonas aeruginosa]]
*Fungi
|-
|-
| <center>'''Diabetes mellitus''' </center>||
 
*[[Staphylococcus aureus|S aureus]]
 
*β-Hemolytic streptococci
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
*[[Streptococcus pneumoniae|S pneumoniae]]
|-
|-
| <center>'''Early (1 y) prosthetic valve placement''' </center>||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
*Coagulase-negative staphylococci
*S aureus
*Aerobic Gram-negative bacilli
*Fungi
*Corynebacterium sp
*Legionella sp
|-
|-
| <center>'''Late (>1 y) prosthetic valve placement''' </center>|| Coagulase-negative staphylococci
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
*S aureus
*Viridans group streptococci
*Enterococcus species
*Fungi
*Corynebacterium sp
|-
|-
| <center>'''Dog–cat exposure''' </center>||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸'''''[[Tobramycin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸ '''''[[Amikacin]] 10 mg/kg IV q8h'''''
*Bartonella sp
*Pasteurella sp
*Capnocytophaga sp
|-
|-
| <center>'''Contact with contaminated milk'''</center>
 
<center>'''Contact with infected farm animals'''</center>
 
||
|}
*Brucella sp
| valign=top |
*Coxiella burnetii
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:19em" cellpadding="0" cellspacing="0";
*Erysipelothrix sp
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age 1—23 Months}}''
|-
|-
| <center>'''Homeless, body lice'''</center>||


*Bartonella sp
 
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| <center>'''AIDS'''</center> ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
*[[Salmonella|Salmonella sp]]
*[[Streptococcus pneumoniae|S pneumoniae]]
*[[Staphylococcus aureus|S aureus]]
|-
|-
| <center>'''Pneumonia, meningitis'''</center>||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
*S pneumoniae
|-
|-
| <center>'''Solid organ transplant'''</center>||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 150—200 mg/kg/day IV q6—8h'''''
*S aureus
*[[Aspergillus|Aspergillus fumigatus]]
*[[Enterococcus|Enterococcus sp]]
*[[Candida albicans|Candida sp]]
|-
|-
| <center>'''Gastrointestinal lesions'''</center>||  
 
*S bovis
 
*Enterococcus sp
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
*Clostridium septicum
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸'''''[[Tobramycin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸ '''''[[Amikacin]] 10 mg/kg IV q8h'''''
|-
|}
|}
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:19em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age 1—4 Weeks}}''
|-


! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 150—200 mg/kg/day IV q6—8h'''''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸'''''[[Tobramycin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸ '''''[[Amikacin]] 10 mg/kg IV q8h'''''
|-
|}


==Empirical Antibiotic Therapy==
==Empirical Antibiotic Therapy==

Revision as of 17:15, 14 January 2014


Meningitis Main Page

Patient Information

Overview

Causes

Classification

Viral Meningitis
Bacterial Meningitis
Fungal Meningitis

Differential Diagnosis

Diagnosis

Treatment

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Medical Therapy

Pharmacotherapy

Empiric Treatment

  • Do not wait for the results of the CT scan and the lumbar puncture; empiric treatment should be started as soon as possible.
  • Blood cultures should be drawn before starting the antibiotic therapy, and then the antibiotic treatment should be changed once the blood culture results are out.
  • Empiric antibiotic treatment should be started within 30 minutes after the patient presentation.
  • In case of high suspicion of pneumococcal meningitis in adult patients, 0.15 mg/kg IV Q6H dexomethasone should be administered for 2 to 4 days.
    • The first dose of dexomethasone is given along with or 20 minutes prior to starting the antibiotics treatment.
Age <1 Week
Preferred Regimen
Ampicillin 50 mg/kg IV q8h
AND
Cefotaxime 100—150 mg/kg/day IV q8—12h
Alternative Regimen
Ampicillin 50 mg/kg IV q8h
AND
Gentamicin 2.5 mg/kg IV q12h


Age <1 Week
Preferred Regimen
Ampicillin 50 mg/kg IV q8h
AND
Cefotaxime 100—150 mg/kg/day IV q8—12h
Alternative Regimen
Ampicillin 50 mg/kg IV q8h
AND
Gentamicin 2.5 mg/kg IV q12h
Age 1—4 Weeks
Preferred Regimen
Ampicillin 200 mg/kg/day IV q6—8h
AND
Cefotaxime 150—200 mg/kg/day IV q6—8h
Alternative Regimen
Ampicillin 200 mg/kg/day IV q6—8h
AND
Gentamicin 2.5 mg/kg IV q8h
OR
Tobramycin 2.5 mg/kg IV q8h
OR
Amikacin 10 mg/kg IV q8h
Age 1—23 Months
Preferred Regimen
Ampicillin 200 mg/kg/day IV q6—8h
AND
Cefotaxime 150—200 mg/kg/day IV q6—8h
Alternative Regimen
Ampicillin 200 mg/kg/day IV q6—8h
AND
Gentamicin 2.5 mg/kg IV q8h
OR
Tobramycin 2.5 mg/kg IV q8h
OR
Amikacin 10 mg/kg IV q8h
Age 1—4 Weeks
Preferred Regimen
Ampicillin 200 mg/kg/day IV q6—8h
AND
Cefotaxime 150—200 mg/kg/day IV q6—8h
Alternative Regimen
Ampicillin 200 mg/kg/day IV q6—8h
AND
Gentamicin 2.5 mg/kg IV q8h
OR
Tobramycin 2.5 mg/kg IV q8h
OR
Amikacin 10 mg/kg IV q8h

Empirical Antibiotic Therapy

  • Although antibiotic therapy for subacute disease can be delayed till the result of blood culture, the rapid progression of acute cases necessitate the start of empirical treatment antibiotic therapy once the blood cultures have been collected.
  • Empirical therapy is needed for all likely pathogens, certain antibiotic agents, including aminoglycosides, is preferably avoided for its toxic effects.
  • Clinical course of infection beside the epidemiological features should be considered upon selecting empirical treatment regimen.
Regimen Dosage and Route Duration(weeks)
Native valve
Ampicillin sulbactam 12 g per 24 h IV in 4 equally divided doses 4–6 weeks
plus
Gentamicin sulfate 3 mg per kg per 24 h IV/IM in 3 equally divided doses 4–6 weeks
or
Vancomycin 30 mg per kg per 24 h IV in 2 equally divided doses 4–6 weeks
plus
Gentamicin sulfate 3 mg per kg per 24 h IV/IM in 3 equally divided doses 4–6 weeks
plus
Ciprofloxacin 1000 mg per 24 h PO or 800 mg per 24 h IV in 2 equally divided doses 4–6 weeks
Pediatric dose:
  • Ampicillin sulbactam 300 mg per kg per 24 h IV in 4–6 equally divided doses
  • Gentamicin 3 mg per kg per 24 h IV/IM in 3 equally divided doses
  • Vancomycin 40 mg per kg per 24 h in 2 or 3 equally divided doses
  • Ciprofloxacin 20–30 mg per kg per 24 h IV/PO in 2 equally divided doses
Prosthetic valve (early, ≤ 1y, , mostly Oxacillin resistent)
Vancomycin 30 mg per kg per 24 h IV in 2 equally divided doses 6 weeks
plus
Gentamicin sulfate 3 mg per kg per 24 h IV/IM in 3 equally divided doses 2 weeks
plus
Cefepime 6 g per 24 h IV in 3 equally divided doses 6 weeks
plus
Rifampin 900 mg per 24 h PO/IV in 3 equally divided doses 6 weeks
Pediatric dose:
  • Vancomycin 40 mg per kg per 24 h IV in 2 or 3equally divided doses
  • Gentamicin 3 mg per kg per 24 h IV/IM in 3 equally divided doses
  • Cefepime 150 mg per kg per 24 h IV in 3 equally divided doses
  • Rifampin 20 mg per kg per 24 h PO/IV in 3 equally divided doses
Prosthetic valve (late—greater than 1 y, mostly Oxacillin sensitive)

Same regimens as listed above for native valve endocarditis

Suspected Bartonella, culture negative
Ceftriaxone sodium 2 g per 24 h IV/IM in 1 dose 6 weeks
plus
Gentamicin sulfate 3 mg per kg per 24 h IV/IM in 3 equally divided doses 2 weeks
with/without
Doxycycline 200 mg per kg per 24 h IV/PO in 2 equally divided doses 6 weeks
Documented Bartonella, culture positive
Doxycycline 200 mg per 24 h IV or PO in 2 equally divided doses 6 weeks
plus
Gentamicin sulfate 3 mg per kg per 24 h IV/IM in 3 equally divided doses 2 weeks
Pediatric dose:
  • Ceftriaxone 100 mg per kg per 24 h IV/IM once daily
  • Gentamicin 3 mg per kg per 24 h IV/IM in 3 equally divided doses
  • Doxycycline 2–4 mg per kg per 24 h IV/PO in 2 equally divided doses
  • Rifampin 20 mg per kg per 24 h PO/IV in 2 equally divided doses


Epidemiological features Common Microorganism(s)
Injection drug use
  • S aureus, including community-acquired
  • oxacillin-resistant strains
  • Coagulase-negative staphylococci
  • β-Hemolytic streptococci
  • Fungi
  • Aerobic Gram-negative bacilli, including
  • Pseudomonas aeruginosa





Treatment Based Upon Infectious Agent[1]

Penicillin-Susceptible Strep Viridans and Other Nonenterococcal Streptococci

Penicillin G

  • If Minimum inhibitory concentration [MIC] <0.2 µg/ml.
  • Dose: 12–18 million units I.V. daily in divided doses q. 4 hour for 4 weeks.

Penicillin G + Gentamicin

  • Dose: Penicillin G, 12–18 million units I.V. daily in divided doses q. 4 hour for 4 weeks plus gentamicin, 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hour for 2 weeks (peak serum concentration should be ~ 3 µg/ml and trough concentrations < 1 µg/ml).

Ceftriaxone

  • Dose: 2 g I.V. daily as a single dose for 2 weeks.

References

  1. Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A. (2005). "Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): 3167–84. PMID 15956145.